The long-term expression and the ability of a therapeutic gene to confer survival advantage to transduced cells are mandatory requirements for successful anti-HIV gene therapy. In this context, we developed lentiviral vectors (LVs) expressing the F12-Vif derivative Chim3. We recently showed that Chim3 inhibits HIV-1 replication in primary cells by both blocking the accumulation of retrotranscripts, independently of either human APOBEC3G (hA3G) or Vif, and preserving the antiviral function of hA3G. These results were predictive of long-lasting survival of Chim3 + cells after HIV-1 infection. Furthermore, Vif, like Vpr, deregulates cell cycle progression by inducing a delay in G2 phase. Thus, the aim of this study was to investigate the role of Chim3 on both cell survival and cell cycle regulation after HIV-1 infection. Here, we provide evidence that infected Chim3 + T-cells prevail over either mock-or empty-LV engineered cells, show reduced G2 accumulation and, as a consequence, ultimately extend their lifespan.
Introduction
A central issue of anti-HIV gene therapy is the ability of the therapeutic gene(s) to confer genetic resistance against viral infection to target cells. This leads to diminish virally-induced cytophatic effects (CPE) and eventually to extend cell survival. However, not all antiviral genes studied so far possess these positive features 1 . In this regard, anti-HIV-1 transgenes have been grouped into three classes depending on the phase of the viral life cycle targeted 1 . Class I genes affect the early steps of HIV-1 life-span ultimately preventing integration of proviral DNA, thus keeping the cells free of new infection; class II genes block viral gene expression thereby reducing the overall production of toxic viral proteins and virions from chronically infected cells; class III genes affect the assembly and release of new infectious viral particles 1 . According to this classification, mathematical models supported by experimental data predict that class I and class II genes protect from viral CPE and induce prolongation of cell life span, whereas class III genes do not. On this basis, the mode of action of an antiviral gene has to be carefully analyzed to achieve a powerful and life-long therapeutic advantage. In this context, we developed preclinical gene therapy technology based on lentiviral vector (LV) expressing a natural mutant of the viral infectivity factor (Vif), named F12-Vif 2 . Vif is an HIV-1 key protein, whose major function is to block the antiviral activity of the cellular restriction factor human apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC)-3G (hA3G) 3, 4 . However, the role of Vif is not limited to counteract hA3G, but it has been proved increasingly complex over time.
Although Vif was implicated in reverse transcription process for long time 5,6 , only recently, it has been demonstrated to directly interact with both HIV-1 reverse transcriptase (RT) and genomic RNA 7-11 . In addition, Vif plays a direct role along with Vpr, though independent of it, For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From in inducing viral cytopathycity and cell cycle delay in G2 phase by recruiting Cul5-ligase complex and degrading a yet-to-be-identified cell factor [12] [13] [14] . Altogether, Vif is rightly considered an important target for antiviral therapy because it is involved in many key viral and cellular processes linked to HIV-1 pathogenesis. We showed that F12-Vif inhibits HIV-1 replication 2 despite degrading hA3G as efficiently as HIV-1 Vif does. As a consequence of a partial characterization of its mechanism of action, F12-Vif was labeled as a class III antiviral transgene 1 . In contrast, being the F12-Vif derivative Chim3 as lethal against HIV-1 as F12-Vif is, but unable to degrade hA3G, and acting as a dominant negative factor affecting the retrotranscripts accumulation and HIV DNA integration, it has to be categorized as a class I antiviral transgenes.
Once established that Chim3 is a potent intracellular inhibitor of HIV-1 replication operating at the pre-integration step of HIV-1 life cycle, the goal of this study was twofold. First, to verify whether HIV-1 infected Chim3-genetically modified cells prolonged their survival in culture compared to control cells. Second, to analyze the possible contribution of Chim3 on the HIVmediated deregulation of the cell cycle. To this end, we set up an experimental model in which Chim3-expressing T cells were mixed with control cells at 1:1 ratio and then infected with HIV-1. The end-point analysis was the survival and possible enrichment of Chim3-expressing cells.
Furthermore, we examined whether Chim3 played any role in regulating cell cycle either by itself or following HIV-1 infection. Interestingly, we established that Chim3-LV induces survival advantage to both CEM A3.01 cells and primary CD4 + T lymphocytes, and prevents the HIV-1
Vif-mediated cell cycle delay in G2 phase. Taken together, these results suggest that a therapeutic approach based upon the engineering of HSCs with Chim3 can give rise to HIV-1 
Materials and methods

Cells
The HEK-293T cells were propagated in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% fetal calf serum (FCS) (EuroClone Ltd, Paignton, United Kingdom) and a combination of penicillin-streptomycin and glutamine (PSG). CEM A3.01 T cell line 15 and ACH-2 cells 16 , were cultivated in RPMI 1640 supplemented with 10% FCS and PSG.
Human CD4 + T lymphocytes were purified from umbilical cord blood (UCB), cultivated, expanded by CD3/CD28 beads, and transduced as previously described 17 .
For survival advantage experiments, cells were analyzed by the Cedex AS20 automated cell culture analyzer (Innovatis AG, GmbH, Bielefeld, Germany) before mixing. For primary CD4 + T lymphocytes, the experiments were performed only when the different cell types were comparable under cell viability, density, size, morphology and aggregation rate parameters.
Production of lentiviral vectors (LVs), transduction, and immune selection of T cells
The lentiviral vectors (LVs), empty-PΔN (empty-LV) and Chim3-PΔN (Chim3-LV), were described in 2 and 17 , respectively. Chim3 encodes the 45-amino acid region corresponding to amino acids 126-170 of the natural mutant F12-Vif inserted in a NL4-3 HIV Vif backbone together with the constitutive PGK-ΔLNGFR selection marker cassette 18 . The green fluorescent protein (GFP)-LV was obtained by substituting the ΔLNGFR with the GFP gene using the XbaI For personal use only. on November 12, 2017. by guest www.bloodjournal.org From and SacII sites in the empty-LV. VSV-G pseudotyped LV stock production, cell transduction, and immune selection were performed as previously described 17 . GFP-expressing cells were selected by the BD FACSVantage™ SE Cell Sorter (BD Biosciences, San Diego, CA).
Fluorescence activated cell sorter (FACS) and cell cycle analysis
The percentage of LV transduction, measured as ΔLNGFR or GFP expression, was evaluated by flow cytometry analysis (FACS Calibur BD Bioscience, San Jose, CA). NGFR level was measured by using either the anti-NGFR-PE antibody (Ab) (C40-1457, BD Pharmingen™, S. Diego, CA) or the anti-NGFR-biotinylated Ab plus the SAv-PerCP reagent (BD Pharmingen™), the latter only for the detection of ΔLNGFR in the GFP-LV:Chim3-LV mixture. The level of CD4 expression was assessed by either the mouse anti-human CD4 clone SK3 (BD Pharmingen™) or RPA-T4 antibodies (eBioscience Inc., San Diego; CA). FACS results were analyzed by the FlowJo software (Tree Star, Inc., Ashland, OR). The intracellular level of p24Gag was measured using the Kc57 either FITC or PE monoclonal Abs (Beckman Coulter, Fullerton, CA) and the BD Cytofix/Cytoperm™-Fixation/Permeabilization kit following manufacturer's instructions (BD Biosciences). The TCR Vβ repertoire was determined using the IOTest® Beta Mark kit following the manufacturer's instructions (Beckman Coulter).
For cell cycle analysis, cells were first synchronized at the G 1 /S border by 0.75 μM aphidicolin (Sigma Chemical Corp., St. Louis, MO) treatment for 16 hours. The drug was removed by several washes with PBS and, after 10 hours of release, cells were either mock-For personal use only. on November 12, 2017. by guest www.bloodjournal.org From infected or infected with the VSV-G pseudotyped Vif-proficient and Vif-and Vpr-deficient Δenv-HIV-1 at a multiplicity of infection (MOI) of 3 in the presence of aphidicolin. The double deficient HIV-1 molecular clone was obtained by removing the SpeI-SalI HXB2 fragment containing two premature stop codons in the Vif and Vpr genes, respectively. The two viruses were produced as described in details in 17 . After 24 hours of infection, aphidicolin was removed and following 16 hours of release, cells were permeabilized and stained with p24Gag-FITC Ab.
Then, 1 × 10 6 -FITC-labelled cells/ml were resuspended in PBS containing 100 μg/ml propidium iodide, 0.1% saponin, 5 mM EDTA, and 50 μg/ml RNase A for 30' at room temperature. Single cells were analyzed using a double discrimination function; relative cell cycle distribution was calculated using the FlowJo software, and fitting curves with the Dean-Jett-Fox model.
HIV-1 infection
Cells were acutely infected at the indicated MOI with either the X4 NL4-3 or the R5 AD8 HIV-1 molecular clones. Single-round infection experiments were performed using GFP-LV and Chim3-LV transduced cells infected with VSV-G pseudotyped Vif-Vpr-proficient and Vif-Vprdeficient HIV-1. After overnight infection, the virus was removed by several washes with PBS and fresh medium added. Seventy two hours later, cells were analyzed for GFP, ΔLNGFR and p24Gag expression by FACS as described in "FACS and cell cycle analysis" section. Reverse transcriptase (RT) assay was performed as described in 2 .
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LV and HIV-1 DNA copy number quantification by real-time PCR
The LV copy number and HIV DNA was measured by TaqMan PCR using an ABI PRISM Gabuzda, at 1:1,000 dilution.
Southern blot analysis
Genomic DNA (gDNA), isolated by the QIAamp Mini kit according to manufacturer's instructions (QIAGEN GmbH, Germany), was resolved on 0.8% agarose gels, after overnight digestion with AflII, blotted onto nylon membranes (Hybond-N, Amersham), hybridized to 1 × 10 6 dpm/ml 32 P-labelled 1-kb ΔLNGFR fragment in PerfectHyb PLUS hybridization buffer (Sigma Chemical Corp.), and visualized by autography.
Statistical analysis
Statistical comparisons were determined by the two-tailed Student's t-test. The level of significance chosen was P values lower than 0.05. The data are presented as means ± SEM.
Results
CEM A3.01 cells are highly susceptible to HIV-1 infection unless protected by Chim3
Recently, we reported that Chim3 protects primary CD4 + T cells and HSCs-derived macrophages from HIV-1 infection by exploiting a dual mechanism acting at the pre-integration level, ultimately resulting in a drastic reduction of HIV-1 DNA integration 17 . These observations . Genetically modified cells were purified (>95% purity), infected with the X4 HIV-1 NL4-3 molecular clone at an MOI of 0.1 and followed over a month for HIV-1 production. In agreement with our previous findings 17 , Chim3-transduced, unlike empty-transduced cells were protected from HIV-1 infection ( Figure 1A ). In empty-LV cells the cytophatic/lethal effect of HIV-1 was detectable at day 21, 5 days after the peak of viral infection (day 16), whereas the viability of infected Chim3-expressing cells remained comparable to that of the uninfected cells (>70%) throughout the entire course of infection ( Figure 1B ). Moreover, unlike empty-LV, Chim3-LV transduced cells did not show down-modulation of CD4 HIV-1 receptor ( Figure 1C ), which is a typical feature of mainly X4 HIV-1 infected cells 19,20 . This finding excludes CD4 down-modulation as a possible additional cause of Chim3-mediated antiviral activity. Finally, we verified whether Chim3-expressing cells resist HIV-1 infection because one or few HIV-1 resistant cell clone emerge. To this aim, we carried out Southern blot analysis of gDNA extracted from empty-LV-and Chim3-LV-transduced cells after 28 days of HIV-1 infection using a ΔLNGFR specific probe. Empty-transduced CD4cells showed a typical clonal genotype, which likely derives from the growth of the few cells outlived to HIV-1 induced cell death ( Figure 1D 
Chim3-LV confers survival advantage to transduced cells under HIV-1 selective pressure
On this basis, we assumed that Chim3 expressing cells should prevail over unmodified cells when both cell types were infected within the same cell culture. To test this hypothesis, CEM A3.01 mock-transduced cells were mixed at 1:1 ratio with Chim3-LV transduced cells. The mixture was either left uninfected (duplicate culture) or infected (6-replicate culture) with NL4-3
HIV-1 at an MOI of 0.01. We measured HIV-1 production by RT activity assay and ΔLNGFR expression, as an estimate of Chim3-LV cells enrichment, by FACS using an anti-NGFR Ab.
The mix population was productively infected reaching the peak of virus release after 25 days (RT activity = 8,248 cpm/μl over the value of 481 cpm/μl measured at day 7 post infection).
Therefore, Chim3-expressing cells were exposed for a long time to the cytophatic/lethal effect of the virus derived from mock-transduced infected cells. Of note, despite this challenging condition, ΔLNGFR staining at 49 days of culture indicated that Chim3-LV cells were highly enriched in the infected mixture as compared to the uninfected one (Figure 2A , 88% vs. 41%), demonstrating that under strong HIV-1 selective pressure only Chim3-LV-transduced cells survive for longer than 3 months ( Figure 2B ). In agreement with the results of Figure 1C , unlike mock-transduced, Chim3-transduced cells did not down-modulate CD4 receptor following HIV-1 challenge ( Figure 2C ). Figure 2D ). Taken together, these results demonstrate that Chim3 is not silenced overtime and its antiviral activity is therefore permanent.
Chim3-LV, but not empty-LV, confers survival advantage under HIV-1 selective pressure
To exclude the contribution of any functional cis-acting elements present in the LV backbone itself, we mixed CEM A3.01 mock:Chim3-LV and mock:empty-LV cells at 1:1 ratio and processed them following the same experimental conditions of Figure 2A Figure   3A ). This result points out that there is no involvement of the LV backbone in inducing or reinforcing the therapeutic potential of Chim3-LV.
Next, to establish the level of HIV-1 infection in CEM A3.01 mock:Chim3 compared to mock:empty mixture, we measured the HIV-1 production by RT activity assay on a per cell basis ( Figure 3B ) along with the integration of HIV-1 DNA on separated mock-transduced and transduced cell populations ( Figure 3C ). It is interesting to note that, despite the initial contribution of mock cells was equal in both mixtures (ca. 60%), the level of HIV-1 production was overall lower in mock:Chim3-LV than in mock:empty-LV mixture ( Figure 3B ). Next, we separated the transduced cells from the corresponding mock cells of both mixtures by ΔLNGFR immune selection, and measured the HIV-1 DNA content in each cell types before the peak of Taken together, these findings demonstrate that the remarkable reduction of HIV-1 production observed in the mock:Chim3-LV cell mixture mostly depends upon the reduction of HIV-1 DNA integration in Chim3-expressing cells.
Chim3 confers survival advantage to transduced CD4 + T lymphocytes following HIV-1 infection
We carried out survival advantage experiments on mock:Chim3-LV and mock:empty-LV CD4 + T lymphocytes mixed at 1:1 ratio, and then infected with HIV-1 AD8 at an MOI of 1 ( Figure 4A and B) . A month after productive infection, uninfected and infected cells were stained for CD4 and ΔLNGFR expression and analyzed by FACS ( Figure 4A and B) . The percentage of ΔLNGFR + cells was overall unchanged in uninfected cells of both mixtures compared to the initial 50%:50% ratio ( Figure 4A and B) , whereas it was greatly increased (85.7%) only in infected mock:Chim3 mix ( Figure 4A, right panel) . We verified the possible clonality of the Chim3-enriched population by evaluating the TCR Vβ repertoire clonogram of the uninfected and infected cells after 40 days of culture ( Figure S1 ). The expansion of the Vβ2 clone, which is in general the most represented subtype in normal T lymphocytes 21 was clearly observed in infected cells ( Figure S1 ). This result suggests that, as opposed to CEM A3.01, primary T cells are prone to clonal expansion after HIV-1 infection.
Then, we wanted to estimate the level of HIV-1 proviral integration also in CD4 + T lymphocytes to sustain our hypothesis that Chim3-expressing cells survive longer because contain less HIV-1 DNA ( Figure 4C ). To this aim, we transduced CD4 + T lymphocytes either with the Chim3-LV or with the green fluorescent protein (GFP)-LV, instead of the empty-LV, as control. After cell sorting by ≥ 95% ΔLNGFR and GFP positivity, transduced cells were mixed at 1:1 ratio. To avoid cell clonality we performed short-term experiments. We infected the cell mix in single round with a VSV-G pseudotyped Δenv-HIV-1 at an MOI of 3 and after 72 hours, we analyzed the intracellular p24Gag expression as a surrogate marker of HIV-1 DNA integration, as shown in Porcellini et al. (2009) 17 . We observed that Chim3 + -infected cells expressed ca. 65% less p24Gag than control cells do ( Figure 4C ), providing support for the fact that these cells, harboring less HIV-1 DNA are supposed to live longer than control cells.
Chim3 itself does not affect cell cycle
In addition to the well-recognized role of HIV Vpr on cell cycle disruption 14 , it has been recently reported that also Vif itself induces a delay in G2, which is independent of the action of hA3G and, interestingly, is exerted through the recruitment of the same E3 ubiquitin ligase complex that is involved in hA3G degradation [12] [13] [14] . Based on this notion, we decided to verify whether, similarly to Vif, Chim3 can deregulate the cell cycle. To this aim, we transduced HEK-293T cells with empty-, WT-Vif-and Chim3-LV at equal copy number (5 copies/cell).
Transduced cells were then transfected with Tat and Rev plasmids to trigger transgene expression. We then assessed both the induction of the Vif proteins by Western blot (Figure 5B Figure 5A ). To determine the amplitude of the delay in G2, the G2:G1 ratio was 12 on Vif and, of interest, we established that, in contrast, Chim3 has no effect, suggesting that it is likely defective in recruiting the Cul5-E3 ligase complex and thereby unable to affect the cell cycle.
This hypothesis was supported by our finding showing that Chim3 binds poorly Zn 22 which is required for Cul5/Vif interaction 23 .
Chim3 poorly interacts with Cul5
To confirm this idea biochemically, we carried out co-immunoprecipitation analysis between Cul5 and Vif proteins ( Figure 5C and D) . HEK-293T cells were transfected with a fix amount of Cul5-HA expression vector and increasing amount of either WT-Vif-Myc ( Figure 5C ) or Chim3 vectors ( Figure 5D ). Quantification of the bands intensity, normalized by the level of the input extract used (WCE) ( Figure S2A ), indicated that Chim3 interacts with Cul5 from 3.5 to 9.3-fold less than WT-Vif ( Figure S2B ).
Large amount of Chim3 affects HIV-1 Vif/Cul5 interaction
Based on this finding, we wondered whether Chim3 could also interfere with the Cul5/WT-Vif interaction and therefore prevent the recruitment of the E3-ligase complex to destroy the yetto-be-identified protein. To answer this question, we transfected fixed amount of Cul5-HA and WT-Vif-Myc and increasing amount of Chim3 vectors, coimmunoprecipitated the protein complexes with anti-HA Abs, and finally revealed them with specific anti-Vif and anti-anti-HA For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Abs ( Figure 5E ). Interestingly, quantification of the bands intensity, normalized by the level of the input extract used (WCE) ( Figure S2C ), established that 4-fold increase of Chim3, produced a decrement of WT-Vif-Myc interaction to Cul5 of ca 50% and an increment in Chim3 interaction of ca. 50% ( Figure S2D, columns 13 vs 8 ). This result indicates that large amount of Chim3 competes with WT-Vif for Cul5 interaction of at least 50% and suggests the formation of possibly non-functional heterodimers or Chim3 homodimers interacting with Cul5.
Chim3 prevents HIV-1 Vif-induced cell cycle delay at the G2 phase in CD4 + T cells
Next, we wished to investigate whether the weak Chim3-Cul5 interaction and the interference of Chim3 on Cul5-Vif binding translated into a direct effect on cell cycle progression in CD4 + T cells. As we showed that transduced T cells, unlike transduced HEK-293T cells, accumulated Vif For personal use only. on November 12, 2017. by guest www.bloodjournal.org From infection with Vif-Vpr-proficient HIV-1 produced from empty-LV transduced HEK-293T cells, the G2:G1 ratio was highest in empty target cells ( Figure 6A ), and slightly lower in Chim3-LV target CEM A3.01 cells ( Figure 6C ). In contrast, after infection with Vif-Vpr-proficient HIV-1 generated from Chim3-LV producer cells, Chim3-target cells showed the lowest ratio among the four conditions ( Figure 6D ). Interestingly, when the cells were infected with Vif-Vpr-deficient HIV-1, the G2:G1 ratios were similar in all conditions ( Figure 6E-H) , indicating a dominant negative function of Chim3. Similarly, the p24Gagcells showed a cell cycle profile similar to that Δvif-Δvpr HIV-1 infected cells ( Figure S3 ). Comparable results were obtained also with purified CD4 + T lymphocytes ( Figure S4 and S5) . Taken together, these results not only provide support for the previous findings on the involvement of Vif in affecting the cell cycle [12] [13] [14] , but also indicate that Chim3 prevents the G2 delay induced by HIV-1 Vif protein, when it is expressed either in target or producer cells. A cumulative effect is appreciated when Chim3expressing target cells are infected with HIV-1 generated from Chim3-producer cells ( Figure   6D ).
Discussion
This study was conducted to investigate whether Chim3 extends the life-span of transduced cells following HIV-1 infection. Owing to the fact that Chim3 belongs to group I anti-HIV-1 transgenes for its mechanism of action 1,17 , we expected it was endowed with the ability to confer survival advantage. Here, we provide evidence that the weak, long-term expression of Chim3 prolongs the existence of Chim3-LV-transduced cells compared to mock-and empty-LVtransduced CEM A3.01 cells and primary CD4 + T lymphocytes after HIV-1 infection. We Interestingly, Chim3 expression affects neither the survival nor the cell cycle progression of uninfected cells, suggesting that the antiviral and surviving functions of Chim3 strictly depend on the presence of HIV-1 Vif, which is a typical dominant negative feature. In contrast to WT-Vif, Chim3 does not induce a delay in G2 phase after infection with a Vif-proficient, but not with a Vif-Vpr-deficient HIV-1. It is well documented that Vpr-induced cell cycle arrest in G2 promotes HIV LTR transcriptional activity, viral production, and the onset of apoptosis in infected cells 14 . Similarly, Vif has been lately implicated in the cell cycle delay in G2, independently of Vpr 12, 13 , by recruiting the same Cul5-E3-ligase complex responsible of the degradation of hA3G and then targeting a yet-to-be-identified cellular protein, different from hA3G, to the proteasome 24 . In this context, we established that Chim3 alone interacts with Cul5 from 3.5-to 9-fold less efficiently than WT-Vif. This result gives credit to our previous data demonstrating that Chim3 binds less efficiently than WT-Vif to a Zn affinity column 22 and to the findings of Giri et al. (2009) 25 showing that the presence of Zn enhances the strength of the interaction of Cul5 with a Vif HCCH peptide by 8-fold. Thus it is conceivable that the F12-Vif specific 5 amino acid mutations of Chim3 located in the Zn-finger motif hinders Zn binding and consequently Cul5 interaction. Most importantly, we have shown that an excess of Chim3 halves the WT-Vif-Cul5 interaction and, at the same time, increases the binding of Chim3-Cul5 suggesting the formation of Chim3 homodimers and/or WT-Vif-Chim3 heterodimers interacting with Cul5. This is supported by the notion that the molar ratio between an HCCH peptide and Cul5 is 2:1 indicating that Vif binds to Cul5 as homodimers 25 . We propose that the inhibitory function of Chim3 on the deregulation of the cell cycle, might derive indirectly from the inhibition of HIV-1 DNA integration 17 , that ultimately results in a reduced total amount of newly synthesized HIV-1 Vif, but also to a direct effect of Chim3 on preventing the degradation of the still unknown cellular protein involved in cell cycle perturbation. We show here that upon
HIV-1 infection, the level of proviral DNA is decreased in Chim3-expressing cells even when
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From these cells are embedded in an environment much more challenging than that represented by the pure (≥ 95% Chim3 + ) CD4 + T lymphocyte and macrophage populations 17 . Indeed, Chim3expressing cells directly in contact with non protected HIV-1 + cells represent an environment closer to the in vivo physiological one, where transduced cells are expected to be, at least initially, a minority. We have also recently reported that Vif acts as an auxiliary factor for HIV-1 reverse transcriptase increasing its rate of association to RNA or DNA templates 22 . Thus collectively, a growing body of evidence sustains the concept that Chim3 acts at multiple levels, some of which, such as the block of HIV-1 DNA integration, the lower binding to a Zn-affinity column, and the prevention of G2 delay of the cell cycle, are all independent of the presence of hA3G.
Based on the results we recently published 17,22 and those presented in this manuscript, we draw the following model of action of Chim3 (Figure 7) . During the first round of HIV-1 infection, the percentage of cells delayed in G2-phase ( Figure 6 ) and the number of Altogether, our preclinical findings are encouraging and warrant the investigation of this approach in an appropriate animal model 26 paving the way towards clinical testing. Potentially, HSCs transduced with Chim3-LV once re-infused into patients might give rise to CD4 + T lymphocytes, which not only resist to HIV-1 infection, but also survive and prevail on the untransduced HIV-1 target cells. In the long term, these genetically-modified functionally active cells might overcome chronically infected cells.
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